International Shares Soar On Pfizer, BioNTech COVID-19 Vaccine Information

News18 Logo

LONDON: International shares surged to document highs after Pfizer on Monday stated its experimental vaccine was greater than 90% efficient in stopping COVID-19, based mostly on preliminary knowledge from a big examine.

Markets rallied as the information was seen a significant victory within the combat towards a pandemic that has killed over a million individuals and roiled the world financial system. The MSCI world fairness index, which tracks shares in 49 nations, and futures monitoring the S&P 500 hit all-time highs.

STORY:

Pfizer, BioNTech say their COVID-19 vaccine is greater than 90% efficient:

MARKET REACTION:

European shares soar 4% to March highs, safe-haven Japanese yen slips 0.5% and spot gold slides 1.2%.

COMMENTS:

CARSTEN BRZESKI, GLOBAL HEAD OF MACRO AT ING:

“The larger driver of the financial outlook is from exterior components. Proper now meaning the event of a vaccine, which is why we’re following information on this entrance carefully.

“The bottom case now we have already is that we’re more likely to get a vaccine by year-end and that will probably be rolled. So we do see information like this as optimistic. The worrying signal can be if we get unfavourable information say on testing, that might harm how we view the financial outlook.”

RUSSELL SILBERTSON, CO-HEAD OF DEVELOPED MARKET FX & RATES AT ASSET MANAGER NINETY ONE

“If the bearish view embedded in markets was that there was no efficient vaccine any time quickly priced in, clearly that wants important repricing now.

“You couple (this morning’s information) that with the sheer weight of all of the stimulus in markets, and that’s a really sturdy financial upside state of affairs.”

CHRIS SCICLUNA, HEAD OF ECONOMIC RESEARCH, DAIWA CAPITAL MARKETS, LONDON

“The excellent news on the vaccine was all the time the upside danger for markets and whether it is developed and rolled out shortly, then that does help the restoration and reflation narrative.

“However now we have do should watch out that the variety of sufferers reporting outcomes are nonetheless very low. So we should be maybe cautiously optimistic about this information and have a look at much more outcomes. The outcomes haven’t been peer reviewed but however it’s optimistic. They (Pfizer) are additionally upping their manufacturing forecasts and that’s optimistic.”

NEIL WILSON, CHIEF MARKET ANALYST AT MARKETS.COM

“While we aren’t there but, information that this vaccine may very well be extremely efficient is the perfect factor markets might hope for. Public well being officers will remind us there’s a lengthy street forward, and lots of challenges will probably be confronted alongside the way in which, however there is a gigantic sense of optimism at this time – gentle on the finish of the tunnel.

“Let’s simply hope the vaccine deniers gained’t get in the way in which, however 2021 simply acquired quite a bit brighter.”

NIKESH PATEL, HEAD OF INVESTMENT STRATEGY, KEMPEN CAPITAL MANAGEMENT, LONDON

“That is the primary information that enables governments to start out planning forward to when economies can correctly begin to reopen from lockdowns. That offers them extra visibility and concreteness about what fiscal coverage they will take.

“Financial coverage can solely go up to now at this level and it must be a fiscal response for an actual restoration and this type of information is nice because it permits governments to make that fiscal response with out worry of infinite help.”

KENNETH BROUX, FX STRATEGIST AT SOCIETE GENERALE

“The COVID 19 vaccine information provides to the optimistic danger tone in shares and underpins excessive beta currencies vs the U.S. greenback. Any optimistic information on vaccine is nice information for the world financial system and affords perspective for rebound/normalisation in 2021 development.”

(Compiled by the International Finance & Markets Breaking Information crew)

Disclaimer: This put up has been auto-published from an company feed with none modifications to the textual content and has not been reviewed by an editor